scispace - formally typeset
J

Julie So

Researcher at University Health Network

Publications -  8
Citations -  1051

Julie So is an academic researcher from University Health Network. The author has contributed to research in topics: Age of onset & Genetic linkage. The author has an hindex of 8, co-authored 8 publications receiving 980 citations. Previous affiliations of Julie So include University of Toronto & Toronto Western Hospital.

Papers
More filters
Journal ArticleDOI

A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease: No Evidence of Benefit

M. Flint Beal, +160 more
- 01 May 2014 - 
TL;DR: Coenzyme Q10 was safe and well tolerated in this population, but showed no evidence of clinical benefit, and the study was terminated after a prespecified futility criterion was reached.
Journal ArticleDOI

Heterozygosity for a mutation in the parkin gene leads to later onset Parkinson disease

Tatiana Foroud, +98 more
- 11 Mar 2003 - 
TL;DR: Mutations in the parkin gene occur among individuals with PD with an older age at onset (≥60 years) who have a positive family history of the disease, and the clinical findings of parkin-positive individuals are remarkably similar to those without mutations.
Journal ArticleDOI

Significant Linkage of Parkinson Disease to Chromosome 2q36-37

Nathan Pankratz, +99 more
TL;DR: This work has expanded the sample to include 150 families meeting the strictest diagnostic definition of verified PD, and performs analyses using only those pedigrees with the strongest family history of PD, which strongly suggests that variation in a gene on chromosome 2q36-37 contributes to PD susceptibility.
Journal ArticleDOI

Genome-wide linkage analysis and evidence of gene-by-gene interactions in a sample of 362 multiplex Parkinson disease families

Nathan Pankratz, +91 more
TL;DR: Findings demonstrate consistent evidence of linkage to chromosomes 2 and X and also support the hypothesis that gene-by-gene interactions are important in PD susceptibility.
Journal ArticleDOI

Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease.

Robert A. Hauser, +137 more
- 15 Mar 2009 - 
TL;DR: Compared to delayed start, early initiation of rasagiline provided long‐term clinical benefit, even in the face of treatment with other dopaminergic agents.